B-type rapidly accelerated fibrosarcoma (BRAF) inhibitors (vemurafenib, dabrafeniband, and encorafenib) and mitogen-activated extracellular signal-regulated kinase (MEK) inhibitors (trametinib, cobimetinib, binimetinib, and selumetinib) are used, alone or in combination, in patients with BRAF-mutated melanoma. This evidence concerns the gene BRAF and fibrosarcoma.